[go: up one dir, main page]

DK1237559T3 - Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran - Google Patents

Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran

Info

Publication number
DK1237559T3
DK1237559T3 DK00982033T DK00982033T DK1237559T3 DK 1237559 T3 DK1237559 T3 DK 1237559T3 DK 00982033 T DK00982033 T DK 00982033T DK 00982033 T DK00982033 T DK 00982033T DK 1237559 T3 DK1237559 T3 DK 1237559T3
Authority
DK
Denmark
Prior art keywords
melagatran
receptor antagonist
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
DK00982033T
Other languages
Danish (da)
English (en)
Inventor
John Dixon
Robert Humphries
Gavin Jarvis
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1237559T3 publication Critical patent/DK1237559T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00982033T 1999-12-01 2000-11-29 Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran DK1237559T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
DK1237559T3 true DK1237559T3 (da) 2006-10-30

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00982033T DK1237559T3 (da) 1999-12-01 2000-11-29 Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran

Country Status (32)

Country Link
US (2) US20030032618A1 (es)
EP (2) EP1719526A3 (es)
JP (1) JP2003515565A (es)
KR (1) KR100785953B1 (es)
CN (1) CN1402639A (es)
AR (1) AR033658A1 (es)
AT (1) ATE332698T1 (es)
AU (1) AU781691B2 (es)
BR (1) BR0016043A (es)
CA (1) CA2391161C (es)
CO (1) CO5271717A1 (es)
CY (1) CY1105211T1 (es)
CZ (1) CZ300925B6 (es)
DE (1) DE60029340T2 (es)
DK (1) DK1237559T3 (es)
EE (1) EE05127B1 (es)
ES (1) ES2267591T3 (es)
HU (1) HU230890B1 (es)
IL (1) IL149495A0 (es)
IS (1) IS2841B (es)
MX (1) MXPA02004871A (es)
MY (1) MY128896A (es)
NO (1) NO331215B1 (es)
NZ (2) NZ518904A (es)
PT (1) PT1237559E (es)
RU (1) RU2242232C2 (es)
SE (1) SE9904377D0 (es)
SI (1) SI1237559T1 (es)
SK (1) SK288707B6 (es)
TW (1) TWI251491B (es)
WO (1) WO2001039781A1 (es)
ZA (1) ZA200203707B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CA2618187C (en) * 2005-09-21 2011-06-21 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
ES2773040T3 (es) 2009-11-11 2020-07-09 Chiesi Farm Spa Métodos de tratamiento o prevención de trombosis de stent
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
EA034550B1 (ru) 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
PL297372A1 (en) * 1991-04-06 1993-09-06 Fisons Plc Atp analogs
ES2108425T3 (es) * 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR100444123B1 (ko) * 1995-07-11 2004-10-14 아스트라제네카 악티에볼라그 신규한혈소판응집억제제
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
WO2004031143A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
EP1652532A1 (en) * 2003-07-16 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
EE05127B1 (et) 2009-02-16
PL355841A1 (en) 2004-05-17
IS2841B (is) 2013-08-15
SK288707B6 (sk) 2019-10-02
AR033658A1 (es) 2004-01-07
KR20020069201A (ko) 2002-08-29
HUP0203585A2 (hu) 2003-03-28
EP1237559A1 (en) 2002-09-11
IL149495A0 (en) 2004-03-28
AU781691B2 (en) 2005-06-09
CY1105211T1 (el) 2010-03-03
SK7502002A3 (en) 2003-02-04
CA2391161A1 (en) 2001-06-07
ZA200203707B (en) 2003-10-29
HUP0203585A3 (en) 2005-01-28
IS6398A (is) 2002-05-27
NZ518904A (en) 2004-02-27
JP2003515565A (ja) 2003-05-07
TWI251491B (en) 2006-03-21
MY128896A (en) 2007-02-28
HU230890B1 (hu) 2018-12-28
NZ530058A (en) 2005-04-29
WO2001039781A1 (en) 2001-06-07
SE9904377D0 (sv) 1999-12-01
RU2242232C2 (ru) 2004-12-20
EP1719526A3 (en) 2007-04-25
EE200200271A (et) 2003-06-16
HK1047893A1 (en) 2003-03-14
CZ300925B6 (cs) 2009-09-09
NO20022606L (no) 2002-07-11
PT1237559E (pt) 2006-10-31
BR0016043A (pt) 2002-07-23
ATE332698T1 (de) 2006-08-15
NO20022606D0 (no) 2002-05-31
DE60029340T2 (de) 2007-07-19
CZ20021887A3 (cs) 2002-11-13
RU2002117296A (ru) 2004-01-20
KR100785953B1 (ko) 2007-12-14
DE60029340D1 (de) 2006-08-24
EP1237559B1 (en) 2006-07-12
US20060270607A1 (en) 2006-11-30
AU1910901A (en) 2001-06-12
MXPA02004871A (es) 2002-08-30
US20030032618A1 (en) 2003-02-13
EP1719526A2 (en) 2006-11-08
CO5271717A1 (es) 2003-04-30
NO331215B1 (no) 2011-11-07
CN1402639A (zh) 2003-03-12
ES2267591T3 (es) 2007-03-16
CA2391161C (en) 2010-10-05
SI1237559T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
DK1237559T3 (da) Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran
IS7324A (is) Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
ATE359064T1 (de) Pharmazeutische tramadolsalze
NO20021719D0 (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
EE9900090A (et) Alfusosiinhüdrokloriidi reguleeritult vabastav tablett
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
DK1035115T3 (da) 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
NO20020859D0 (no) PH-1, en reseptor for B7-4 og anvendelser derav
NO20015931D0 (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
IL146632A0 (en) Pharmaceutical tablets
NO990243D0 (no) Trovafloxacin-mesylat-tablett
DK1275397T3 (da) Lægemiddel til lokal anvendelse
ATE305920T1 (de) Bradykinin receptorantagoniste
NL1017143A1 (nl) Glazen voorwerp en glassubstraat voor een beeldplaat.
NO20013997D0 (no) Reseptoranalyse
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
IS6723A (is) 10-arýl-11H-bensó[b]flúorenafleiður og hliðstæðurtil lyfjanotkunar
NO20035798L (no) Tablett som inneholder cetirizin og pseudoefedrin
NO20014224L (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
AR025867A1 (es) Formulacion portasdora farmaceutica
IS6163A (is) Lyfjakomplex
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
NO20021475D0 (no) Vasopressinantagonist, formulering og fremgangsmåte
NO991359D0 (no) Tablettdispenser